This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B20.4 (HIV disease resulting in candidiasis) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration) |
| B. Synonyms | HIV candidiasis, HIV-associated oropharyngeal candidiasis, HIV-associated esophageal candidiasis, AIDS-defining candidiasis, HIV-associated mucocutaneous candidiasis, thrush in HIV |
| C. Adult onset | Likelihood of first onset in adulthood: very high — occurs frequently in HIV-infected adults when the CD4 count is below 200/μL, and esophageal candidiasis, an AIDS-defining illness, mainly presents in adults in their 30s–50s. Pathophysiologically different from thrush in neonates and children. |
| 1. History | Oropharyngeal candidiasis included in the first CDC description defining AIDS in 1981 → esophageal candidiasis confirmed as an AIDS-defining illness in the 1987 revised CDC AIDS surveillance definition → case reports of fluconazole-resistant C. albicans and non-albicans Candida in the 1990s → incidence fell sharply after ART in 1996 → fluconazole prophylaxis guidelines established in the 2000s. |
| 2. Causes | Main causative organisms: Candida albicans (80%), C. glabrata, C. tropicalis, C. krusei. HIV immunosuppression → decreased CD4+ T cells → collapse of mucosal immunity → overgrowth of endogenous Candida. Resistant organisms emerge with long-term fluconazole use. Gastric acid suppressants, broad-spectrum antibiotics, and steroids are also risk factors. |
| 3. Genetics | Dectin-1 (CLEC7A) gene polymorphism → reduced β-glucan recognition → increased susceptibility to Candida. Deficiency of the IL-17A/IL-17F signaling pathway causes chronic mucocutaneous candidiasis. STAT3 gain-of-function mutation: increased mucosal candidiasis in hyper-IgE syndrome (Job syndrome). Candida ERG11 gene mutation: azole resistance. FKS1/FKS2 mutation: echinocandin resistance. |
| 4. General epidemiology | Before ART, 80–90% of HIV patients experienced oropharyngeal candidiasis in their lifetime. Esophageal candidiasis: 10–20% of AIDS patients. Incidence decreased by 70–80% after the introduction of ART. Still a major cause of morbidity in patients without ART access in low-income countries. In HIV patients in Korea, candidiasis is one of the leading causes of early AIDS-defining illness. |
| 5. Epidemiology in Korea | KDCA HIV/AIDS notification status and clinical cohort data: the rate of candidiasis co-occurrence at the time of AIDS manifestation in HIV patients in Korea is about 15–25%. Esophageal candidiasis is an AIDS-defining illness requiring endoscopic confirmation and ranks high among causes of HIV-related admission in Korea. Isolation of resistant Candida is rare but increasing among long-term prophylaxis users. |
| 6. Pathophysiology | Normal mucosa: Th17 cells · secretory IgA · neutrophils → suppress Candida. HIV infection → decreased CD4 T cells, especially early depletion of gut mucosal Th17 cells → collapse of mucosal defense → Candida switches to hyphal form → mucosal invasion. Esophageal involvement: occurs at low CD4 (usually <100/μL). Unlike mucosal candidiasis, hematogenous dissemination (candidemia) requires additional risk factors (central venous catheter, organ transplantation, anticancer therapy). |
| 7. Clinical features | Oropharyngeal candidiasis: white plaques on the tongue, buccal mucosa, and pharynx, with erythema and bleeding when wiped off; oral burning and taste disturbance. Esophageal candidiasis: odynophagia and dysphagia are characteristic; endoscopy required. Vaginal candidiasis: recurrent and refractory. Cutaneous candidiasis: intertriginous areas. Rarely laryngeal and bronchial involvement. Diagnosis of esophageal candidiasis → immediate CD4 count and quantitative HIV RNA required. |
| 8. Tests and diagnosis | Oropharyngeal: clinical diagnosis possible (white plaques + erythema). Confirmation: KOH smear (identify hyphae and pseudohyphae), fungal culture (Sabouraud medium). Esophageal candidiasis: diagnosed by endoscopy (white plaques, tissue biopsy PAS staining) or by response to empirical fluconazole. Serum beta-D-glucan: used for screening for invasive candidiasis. Resistance testing: susceptibility testing of the isolate when azole treatment fails. |
| 9. Treatment | Oropharyngeal: fluconazole 100mg/day for 7–14 days is first choice. Alternatives: oral itraconazole, clotrimazole troches. Esophageal candidiasis: fluconazole 100–400mg/day for 14–21 days. Resistant (C. krusei, C. glabrata): voriconazole or echinocandin (caspofungin, micafungin). Starting ART is the fundamental treatment; recurrence decreases with CD4 recovery. Consider the possibility of IRIS. Candidemia: echinocandin preferred. |
| 10. Prognosis | Direct mortality from mucosal candidiasis itself is low. Recurs repeatedly without ART. Once CD4 recovers to 200/μL or above with ART, recurrence of candidiasis and secondary prophylaxis are unnecessary. Esophageal candidiasis: good prognosis with ART initiation + fluconazole treatment after diagnosis. Treatment becomes more difficult if azole resistance develops. Hematogenously disseminated candidiasis has a high mortality of 30–40%. |
| 11. Latest findings | Latest DHHS/IDSA guidelines: intermittent fluconazole prophylaxis (three times a week) recommended for frequently recurrent oropharyngeal candidiasis. ART optimization is the best prevention. Enhanced resistance surveillance for non-albicans Candida (including C. auris). Ibrexafungerp (triterpenoid antifungal) FDA-approved (2021): indicated for azole-resistant vaginal candidiasis. New drugs such as fosmanogepix are in clinical trials. |
| 12. Prevention | Primary prevention: maintaining CD4 >200/μL by sustaining ART is best. Thorough oral hygiene (mouth rinsing, denture care). Secondary prevention (preventing recurrence): fluconazole 100–200mg/day or three times a week — if CD4 <100/μL and recurrences are repeated. Can be stopped if CD4 of 200/μL or more is sustained. Azole resistance surveillance is needed during long-term prophylaxis. |
| 13. References | Pappas PG et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America and 9 other papers |
Candidiasis is an opportunistic infection that began together with the history of HIV/AIDS. The concept of AIDS was formed when the CDC in 1981 reported immunodeficiency cases in gay men with oropharyngeal candidiasis and Pneumocystis pneumonia. From that time, oropharyngeal candidiasis was recognized as an early clinical marker of HIV infection.
In the 1987 revised CDC AIDS surveillance definition, esophageal, bronchial, and pulmonary candidiasis were officially included as AIDS-defining illnesses. In the 1990s, fluconazole was introduced clinically and changed the treatment paradigm for candidiasis, but at the same time the emergence of resistance in Candida glabrata and C. krusei due to long-term fluconazole use began to be reported.
The introduction of highly active antiretroviral therapy (HAART) in 1996 dramatically reduced the incidence of candidiasis. It was clinically confirmed that immune reconstitution through CD4 recovery is the most effective means of preventing candidiasis. In the 2000s, fluconazole prophylaxis guidelines and treatment algorithms were established as guidelines of international societies, and the 2016 IDSA guidelines are currently used as the standard.
Fungi of the genus Candida exist as normal commensals on the oral, gastrointestinal, and vaginal mucosa of healthy people. As immunosuppression progresses in HIV infection, endogenous Candida overgrows and causes mucosal disease. The main causative organisms are as follows.
Risk factors: CD4 <200/μL (CD4 <100/μL for esophageal candidiasis), broad-spectrum antibiotic use, corticosteroids, gastric acid suppressants (PPIs), chemotherapy, diabetes, denture wearing.
Host genetic factors influence susceptibility to candidiasis. Individuals carrying the Y238X stop codon polymorphism of the Dectin-1 (CLEC7A) gene have reduced ability to recognize β-1,3-glucan and are vulnerable to recurrent Candida infection. A study conducted in the Netherlands showed that carriers of this variant have an increased risk of gastrointestinal candidiasis.
The IL-17A/IL-17F axis and the STAT3 signaling pathway are central to mucosal anti-Candida defense. Mutations in the IL-17RA, IL-17RC, and ACT1 genes cause chronic mucocutaneous candidiasis (CMC). In HIV, Th17 cells in this pathway are depleted early in the gut mucosa, collapsing Candida defense.
Fungal genes: C. albicans ERG11 (lanosterol 14α-demethylase) mutation → reduced affinity for fluconazole. Overexpression of CDR1/CDR2 (efflux pumps) → azole resistance. Echinocandin resistance: FKS1/FKS2 hot spot mutations → reduced affinity of 1,3-β-D-glucan synthase.
In the pre-ART era (1985–1995), 80–90% of HIV patients experienced oropharyngeal candidiasis at least once in their lifetime, and esophageal candidiasis occurred in 10–20% of AIDS patients. At that time it was a leading cause of AIDS-defining illness.
After the introduction of ART, the incidence of mucosal candidiasis in developed countries fell sharply by 70–80%. However, it remains a major opportunistic infection in low-income countries without access to ART. Worldwide, an estimated 400,000 people each year experience HIV-related esophageal candidiasis.
The emergence of resistant Candida increased after long-term fluconazole prophylaxis in end-stage AIDS patients with CD4 <50/μL. In patients whose ART is now optimized, treatment failure due to resistant strains has become a greater clinical challenge than candidiasis itself.
In Korea, epidemiologic data based on KDCA HIV/AIDS notification status data and university hospital infectious disease cohorts have been published. The rate of candidiasis co-occurrence at the time of AIDS diagnosis after HIV infection is confirmed is reported to be about 15–25%, of which oropharyngeal candidiasis accounts for the majority, and esophageal candidiasis, an AIDS-defining illness requiring endoscopic confirmation, ranks high among causes of admission.
In Korea, the ART treatment rate of HIV patients has improved to over 90% in the 2020s, and accordingly the frequency of candidiasis is decreasing. However, because late HIV diagnosis (late presenter)—first diagnosed with CD4 below 200/μL—accounts for 30–40% of new HIV infections, early manifestation of candidiasis in these individuals is clinically important.
Isolation of resistant Candida is still rare in Korea, but the isolation frequency of C. glabrata and C. krusei is increasing in long-term fluconazole prophylaxis users and severely immunocompromised patients, and antifungal resistance surveillance at HIV-dedicated medical institutions in Korea is being emphasized.
Under normal immune conditions, mucosal defense against Candida is achieved through the combined action of the epithelial barrier, secretory IgA, neutrophils, macrophages, and Th17 cells (secreting IL-17). As HIV infection progresses, this defense system collapses at multiple levels.
From early in infection, HIV preferentially depletes Th17 cells of the gut mucosa. IL-17A and IL-22 secreted by Th17 cells induce epithelial cell secretion of antimicrobial peptides (β-defensin, S100 proteins) and suppress hyphal invasion. When these cells decrease, hyphal switching and mucosal invasion of Candida become easier.
C. albicans expresses virulence as it switches from the yeast form to the hyphal and pseudohyphal forms. Candidalysin (a peptide toxin) at the hyphal tip destroys epithelial cell membranes, and hypha-specific surface proteins (Als, Hwp1) strengthen mucosal adhesion. Proteases (Sap) and phospholipases promote tissue destruction.
The esophagus is involved at lower CD4 counts (usually <100/μL) than the oropharynx. Immune surveillance of the esophageal mucosa is more vulnerable, and an environment lacking gastric acid (e.g., PPI use) promotes Candida growth. Spread to hematogenous dissemination (candidemia) is uncommon with mucosal candidiasis alone and the risk rises when central venous catheters or invasive organ procedures are added.
The pseudomembranous form is most common, with white or cream-colored plaques forming on the tongue, buccal mucosa, and pharynx. When the plaques are wiped off, an erythematous, bleeding surface is revealed. Oral burning, taste disturbance, and discomfort when eating accompany. The erythematous form presents as redness and smoothing of the dorsum of the tongue and is easily overlooked. Angular cheilitis presents as cracking and redness at the corners of the mouth.
As an AIDS-defining illness, odynophagia and dysphagia are characteristic. Retrosternal pain may accompany. In a substantial number of cases the esophagus is involved alone without oropharyngeal candidiasis, so esophageal candidiasis must always be considered in HIV patients complaining of odynophagia.
In women with HIV it is recurrent and refractory, characterized by cheese-like white discharge and vulvar itching and redness. When CD4 is low, a chronic recurrent form recurring two or more times a month is seen.
Characterized by sharply demarcated redness and satellite lesions in intertriginous areas (axilla, groin, inframammary area, diaper area).
Oropharyngeal candidiasis can mostly be diagnosed clinically. With characteristic white plaques and erythema and a background of HIV immunosuppression, empirical treatment can be started.
Beta-D-glucan (β-D-glucan): used for screening for invasive candidiasis (candidemia). Sensitivity 70–80%. Beware of false positives (albumin administration, some antibiotics, PCP). Candida mannan and anti-mannan antibody tests: used at some European institutions.
In HIV patients with odynophagia, a good response after empirical fluconazole treatment (3–5 days) allows a diagnosis of esophageal candidiasis. If there is no response, endoscopy is used to differentiate CMV esophagitis, HSV esophagitis, aphthous ulcers, etc.
First choice: fluconazole 100mg orally once daily for 7–14 days. Superior in convenience of administration and effectiveness. Alternatives: itraconazole oral solution 200mg/day (fasting), clotrimazole troches (10mg dissolved 5 times daily), nystatin oral suspension (no resistance but lower efficacy). Topical preparations have lower systemic exposure and thus lower resistance risk but are less convenient.
Fluconazole 100–400mg/day orally or intravenously for 14–21 days. If dysphagia is severe, start intravenously and then switch to oral. On treatment failure: voriconazole 200mg twice daily or echinocandin (caspofungin 50mg/day IV, micafungin 150mg/day IV, anidulafungin 100mg/day).
Echinocandin is the first choice. Alternative: intravenous amphotericin B lipid formulation. If resistance develops during therapy, changing the drug and susceptibility testing are essential.
Starting (or optimizing) ART at the same time as antifungal treatment is essential for long-term prevention. Once CD4 recovers to 200/μL or above, recurrence decreases even without candidiasis prophylactic drugs. Some ART drugs (rifabutin, rifampin, some PIs) affect fluconazole metabolism, so drug interactions need to be checked.
The direct mortality of mucosal candidiasis alone is very low. However, because a diagnosis of esophageal candidiasis reflects severe immunosuppression in HIV infection (CD4 <100/μL), it should be regarded as a precursor of other AIDS-defining illnesses such as PCP and CMV retinitis if ART is not given.
Once CD4 recovery after ART initiation (200/μL or above) is achieved, recurrence of candidiasis decreases markedly and secondary prophylactic drugs can be stopped. If azole resistance develops, treatment options are limited, with prolonged hospitalization, increased costs, and reduced quality of life.
Unlike mucosal candidiasis, hematogenously disseminated candidiasis (candidemia) has a mortality of 30–40%, which is mainly the result of a combination of severe immunosuppression and healthcare-related factors such as central venous catheters.
In 2021 the FDA approved ibrexafungerp (a triterpenoid antifungal, Brexafemme) for vulvovaginal candidiasis. Its mechanism of action differs from azoles (inhibition of 1,3-β-D-glucan synthase), so there is no cross-resistance, and it has the advantage of oral administration.
Clinical trials of ibrexafungerp for prevention of recurrent candidiasis (CANDLE study) and for treatment of invasive candidiasis are ongoing. Fosmanogepix (Gwt1 inhibitor) and olorofim (dihydroorotate dehydrogenase inhibitor) are also in phase 2/3 clinical trials for resistant Candida and mold infections.
Candida auris is a multidrug-resistant emerging Candida to which hospitalized HIV patients may also be exposed, and surveillance at medical institutions in Korea and abroad is being strengthened. The DHHS 2023 guidelines recommend intermittent fluconazole prophylaxis (three times a week) for recurrent oropharyngeal candidiasis, while emphasizing that fundamental prevention through ART optimization is the most effective.
The key to preventing candidiasis is maintaining a CD4 count of 200/μL or above by sustaining ART. When CD4 is kept high, both oropharyngeal and esophageal candidiasis are effectively prevented. Routine primary fluconazole prophylaxis is not recommended in current guidelines because of the possible emergence of resistant strains.
Regular tooth brushing, use of chlorhexidine mouthwash, and denture hygiene (removing dentures overnight and storing them in an antifungal solution) help suppress oropharyngeal candidiasis. Users of inhaled steroids should rinse the mouth thoroughly after inhalation.
In patients with repeatedly recurrent oropharyngeal candidiasis in whom CD4 recovery through ART is difficult, intermittent prophylaxis with fluconazole 100–200mg/day or three times a week is recommended. If CD4 remains at 200/μL or above, prophylactic dosing can be stopped. During long-term prophylaxis, consider periodic fungal cultures to monitor for azole resistance.
Secondary prevention of esophageal candidiasis: fluconazole 100–200mg/day; consider stopping when CD4 of 200/μL or more + viral suppression is achieved. Unlike other invasive tissue fungal infections (PCP, CMV), the criterion for stopping secondary prophylaxis of candidiasis is CD4 200/μL.